Chimerix, Inc. (NASDAQ:CMRX) Q3 2024 Earnings Call November 7, 2024 8:30 AM ET

Company Participants

Will O’Connor - Investor Relations
Mike Andriole - President and Chief Executive Officer
Josh Allen - Chief Scientific Officer
Michelle LaSpaluto - Chief Financial Officer
Allen Melemed - Chief Medical Officer
Tom Riga - Chief Operating and Commercial Officer

Conference Call Participants

Maury Raycroft - Jefferies

Operator

Good morning, ladies and gentlemen and welcome to the Chimerix Third Quarter 2024 Earnings Conference Call. I would now like to introduce you to your host for today’s call, Will O’Connor from Stern Investor Relations. Please proceed.

Will O’Connor

Thank you, operator. Good morning, everyone and welcome to the Chimerix third quarter 2024 financial and operating results conference call. This morning, we issued a press release related to our third quarter operating update. You can access the press release in our Investors section of the website.

With me on today’s call are President and Chief Executive Officer, Mike Andriole; Chief Scientific Officer, Josh Allen; Chief Financial Officer, Michelle LaSpaluto; Chief Medical Officer, Allen Melemed; and Chief Operating and Commercial Officer, Tom Riga, for questions.

Before we begin, I’d like to remind you that the statements made on today’s call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors. These risks and uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. Please refer to our filings with the SEC for a more complete disclosure of these risks and uncertainties.

At this time, I’ll now turn the call over to President and Chief Executive Officer, Mike Andriole.

Mike Andriole

Thank you, Will. Good morning, everyone, and thanks for joining us. The third quarter was marked by continued execution across our pipeline, including continued enrollment in our global Phase 3 ACTION study of Dordaviprone, and we are nearing complete enrollment of our Phase 1 dose escalation studies for our second-generation imipridone ONC206. The Phase 3 ACTION study is active in 15 countries worldwide, and our first interim data readout is potentially less than a year away.

During this past quarter, we received confirmation from the prespecified interim safety review undertaken by the study’s independent Data Monitoring Committee, which recommended the ACTION study continue as is with no change to study conduct. This is always welcome news, but even more so in the case of the ACTION study, where we have two treatment arms, one at the Phase 2 625-milligram dose administered once per week and a second treatment arm administering 625 milligrams twice per week on consecutive days or essentially a double dose of the Phase 2 schedule.